ndc international 1 an overview of the japanese life sciences industry introduction to collaboration opportunities for german biotech companies in japan biotop forum biobusiness 29 april 2004 fred du plessis limited 2 g167 synopsis where is today government strategy address new drug development pharmaceutical sector structural issues consolidation and critical mass biotechnology evolution focus firms clusters research landscape bio innovation centers deductions conclusions cooperation how positioned assist you agenda 3 a combination factors has slowed down reduced competitiveness economic stagnation during past 12 years deteriorating high production costs healthcare budget remaining fixed slow commercialisation as result regulation underdeveloped venture capital market aging population requiring increased expenditure until recently lack consensus on future small medium sized
